Form 4: Fennec Pharmaceuticals CFO Robert Andrade Reports Share Release

Robert Andrade, CFO of Fennec Pharmaceuticals, reports the release of 1,042 common shares from restriction on February 28, 2025, resulting in a total beneficial ownership of 131,549 shares.

Summary

• On February 28, 2025, Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, reported a transaction involving the release of restricted common shares.
• A total of 1,042 common shares were released from restriction.
• These shares were originally awarded on March 31, 2023.
• Following this transaction, Andrade's total beneficial ownership of Fennec Pharmaceuticals common shares is 131,549.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard reporting of share release, neither particularly positive nor negative.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. It allows investors to track the buying and selling activity of key executives, which can sometimes provide insights into their perspective on the company's performance and future prospects.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine release of previously awarded shares.

Key Dates